| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 |
8-K: Other Events
We have acted as counsel to Zenas BioPharma, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3ASR (the “Registration Statement”) filed on October 8, 2025 by the Company with the Secur... |
| 06 Nov 2026 | 424B5 |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
- PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 - |
| 27 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease |
| 11 Sep 2026 | S-3ASR |
| 11 Sep 2026 | FORM S-8 |
| 08 Sep 2026 | SCHEDULE 13G |
| 08 Sep 2026 |
Form 3: InnoCare Pharma Inc., 10% owner
Holds 7,000,000 shares of Common Stock |
| 08 Sep 2026 | SCHEDULE 13G/A |
| 02 Sep 2026 |
Form 4: Oliger Christy J., Director
Granted 37,000 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 3: Oliger Christy J., Director
No securities owned |
| 19 Aug 2026 | SCHEDULE 13D/A |
| 19 Aug 2026 | 144 |
| 17 Aug 2026 | SCHEDULE 13D/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - |
Loading...